Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
11:48:19 EDT Sat 27 Apr 2024
Enter Symbol
or Name
USA
CA



Sirona Biochem Corp
Symbol SBM
Shares Issued 226,309,320
Close 2020-05-25 C$ 0.30
Market Cap C$ 67,892,796
Recent Sedar Documents

Sirona Biochem shareholders elect five directors at AGM

2020-05-25 19:37 ET - News Release

Subject: URGENT - Sirona Biochem - 2020 AGM - News Release for Immediate Dissemination PDF Document File: Attachment SironaBiochemNR2020May25.pdf SIRONA BIOCHEM ANNOUNCES RESULTS OF ANNUAL GENERAL MEETING Vancouver, British Columbia May 25, 2020 Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US- OTC:SRBCF) (the "Company" or "Sirona Biochem") announces that the Annual General Meeting of the Company (the "AGM") was held at the offices of Sirona Biochem at Suite 1600 - Room 16D 595 Burrard Street, Vancouver, B.C. on Friday, May 22, 2020, at 9:00 a.m. (Pacific Time). All resolutions presented to the shareholders at the AGM were passed, as discussed in the meeting proxy materials published and mailed to the shareholders and posted at www.sedar.com. Voting Results 1. The number of directors of the Company was set at five (5); 2. All directors were elected with more than 96% of votes in favour, being the following directors elected at the AGM: Howard J. Verrico, Christopher D. Hopton, Geraldine Deliencourt- Godefroy, Alex Marazzi and Jason Tian; 3. The ordinary resolution to ratify and approve the Stock Option Plan for continuation was passed by more than 97% of votes in favour; and 4. The ordinary resolution to ratify and approve the Shareholder Rights Plan Agreement was passed by more than 97% of votes in favour. About Sirona Biochem Corp. Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona Biochem's subsidiary lab, TFChem, specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential. Sirona Biochem's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. For more information, please visit www.sironabiochem.com. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. For further information regarding this press release, please contact: Investor Enquiries: Jonathan Williams, Managing Director, Momentum PR, Phone: 1.450.332.6939, Email: jwilliams@momentumpr.com; Corporate Enquiries: Dr. Howard Verrico, CEO, Chairman of the Board, Sirona Biochem Corp., Phone: 1.604.641.4466, Email: info@sironabiochem.com Forward Looking Information Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are -2- cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward- looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

© 2024 Canjex Publishing Ltd. All rights reserved.